Pharmacologic testing of the reversibility of an increased pulmonary vascular resistance before heart transplantation with prostaglandin I2 (prostacyclin);Pharmakologische testung der reversibilitat eines erhohten lungengefasswiderstandes vor herztransplantation mit prostaglandin I2 (prostacyclin)

Zeitschrift fur Kardiologie

Volumn 88, Issue 2, 1999, Pages 133-140

  Trautnitz, M ^a   Pehlivanli, S ^a   Behr, J ^a   Schwaiblmair, M ^a   Uberfuhr P ^a   Meiser, B ^a   Von Scheidt, W ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Heart transplantation; Prostaglandin I2; Pulmonary vascular resistance; Responder classification

Indexed keywords

PROSTACYCLIN DERIVATIVE; PROSTACYCLIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DEMOGRAPHY; DRUG EFFECT; DRUG RESPONSE; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HEART TRANSPLANTATION; HEMODYNAMIC MONITORING; HUMAN; LUNG CAPILLARY PRESSURE; LUNG VASCULAR RESISTANCE; RISK FACTOR; THERMODILUTION; DOSE RESPONSE; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; PULMONARY VEIN; VASCULAR RESISTANCE;

DOSE-RESPONSE RELATIONSHIP, DRUG; EPOPROSTENOL; FEMALE; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PULMONARY VEINS; VASCULAR RESISTANCE;

EID: 0033073225     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003920050269     Document Type: Article

References (31)

1. Addonizio LJ, Gersony WM, Robbins RC, Drusin RE, Smith CR, Reison DS, Reemtsma K, Rose EA (1987) Elevated pulmonary vascular resistance and cardiac transplantation. Circulation 76 (suppl V):V-52
2. Arbeitsgruppe Thorakale Organtransplantation der Deutschen Gesellschaft für Kardiologie - Herz- und Kreislaufforschung (1996) Indikationen, Kontraindikationen und differentialtherapeutische Alternativen der Herztransplantation. Z Kardiol 85:519-527
3. Baudouin SV, Bath P, Du Bois R, Evans TW (1993) L-Arginin infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamics in patients with elevated pulmonary vascular resistance. Br J Clin Pharmac 36:45-49
4. Bourge RC, Kirklin JK, Naftel DC, White C, Mason DA, Epstein AE (1991) Analysis and predictors of vascular resistance after cardiac transplantation. J Thorac Cardiovasc Surg 101:432-45
5. Bourge RC, Naftel DC, Costanzo-Nordin MR, Kirklin JK, Young JB, Kubo SH, Olivari MT, Kasper EK, and the Transplant Cardiologists Research Database Group (1993) Pretransplantation risk factors for death after heart transplantation: a multiinstitutional study. J Heart Lung Trasnplant 12:549-62
6. Chen JM, Levin HR, Michler RM, Prusmack CJ, Rose EA, Aaronson KD (1997) Cardiac and pulmonary replacement. Reevaluating the significance of pulmonary hypertension before cardiac transplantation: determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality. J Thorac Cardiovasc Surg 114:627-34
7. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE (1992) An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327:70-5
8. Cooper CJ, Landzberg MJ, Anderson TJ, Charbonneau F, Creager MA, Ganz P, Selwyn AP (1996) Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation 93:266-271
9. Costanzo MR, Augustine S, Bourge R, Bristow M, O'Connell JB, Driscoll D, Rose E (1995) AHA Medical/Scientific Statement. Selection and treatment of candidates for heart transplantation. Circulation 92:3593-3612
10. Costard-Jäckle A, Fowler MB (1992) Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: Testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 19:48-54
11. Deeb GM, Bolling SF, Guynn TP, Nicklas JM (1989) Amrinone versus conventional therapy in pulmonary hypertensive patients awaiting cardiac transplantation. Ann Thorac Surg 48:665-9
12. Erickson KW, Costanzo-Nordin MR, O'Sullivan EJ, Johnson MR, Zucker MJ, Pifarré R, Lawless CE, Robinson JA, Scanlon PJ (1990) Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation. J Heart Transplant 9:526-37
13. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid W, Steward DJ (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328:1732-1739
14. Haywood GA, Sneddon JF, Bashir Y, Jennison SH, Gray HH, McKenna WJ (1992) Adenosin infusion for the reversal of pulmonary vasoconstriction in biventricular failure. Circulation 86:896-902
15. Higenbottam T (1994) Pathophysiology of pulmonary hypertension. Chest 105/2:7S-12S
16. Kieler-Jensen N, Milocco I, Ricksten SE (1993) Pulmonary vasodilatation after heart transplantation. A comparison among prostacyclin, sodium nitroprusside, and nitroglycerin on right ventricular function and pulmonary selectivity. J Heart Lung Transplantat 12:179-84
17. Kieler-Jensen N, Ricksten SE, Stenqvist O, Bergh CH, Lindelöv B, Wennmalm A, Waagstein F, Lundin S (1994) Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. J Heart Lung Transplant 13:366-75
18. 1, and sodium nitroprusside. J Heart Lung Transplant 14:436-43
19. Kirklin JK, Naftel DC, Kirklin JW, Blackstone EH, White-Williams C, Bourge RC (1988) Pulmonary vascular resistance and the risk of heart transplantation. J Heart Transplant 7:331-336
20. Kirklin JK, Naftel DC, McGiffin DC, McVay RF, Blackstone EH, Karp RB (1988) Analysis of morbid events and risk factors for death after cardiac transplantation. J Am Coll Cardiol 11:917-24
21. Metha S, Steward JD, Langleben D, Levy RD (1995) Short-term pulmonary vasodilatation with 1-arginine in pulmonary hypertension. Circulation 92:1539-45
22. 1 in the pretransplantation evaluation of heart failure patients with significant pulmonary hypertension. J Heart Lung Transplant 11:716-23
23. Murali S, Kormos RL, Uretsky BF, Schechter D, Reddy S, Denys BG, Armitage JM, Hardesty RL, Griffith BP (1993) Preoperative pulmonary hemodynamics and early mortality after orthotopic cardiac transplantation: the Pittsburgh experience. Am Heart J 126:896-904
24. Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS, Rich S (1995) Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 26:1581-5
25. Porter TR, Taylor DO, Cycan A, Fields J, Bagley CW, Pandian NG, Mohanty PK (1993) Endothelium-dependent pulmonary artery responses in chronic heart failure: influence of pulmonary hypertension. J Am Coll Cardiol 22:1418-24
26. Stamler JS, Loh E, Roddy MA, Currie KE, Creager MA (1994) Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 89:2035-2040
27. Stibich Pascual JM, Fiorelli AI, Bellotti GM, Stolf NAG, Jatene AD (1990) Prostacyclin in the management of pulmonary hypertension after heart transplantation. J Heart Transplant 9:644-51
28. Tsutamoto T, Wada A, Maeda Y, Adachi T, Kinoshita M (1994) Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 23:1427-33
29. Vane JR, Botting RM (1995) Pharmacologic profile of prostacyclin Am J Cardiol 75:3A-10A
30. Weiss CI, Park JV, Bolman RM (1989) Prostaglandin E, for treatment of elevated pulmonary resistance in patients undergoing cardiac transplantation. Transpl Proc 21:2555-6
31. Yui Y, Nakajima H, Kawai C, Murakami T (1982) Prostacyclin therapy in patients with congestive heart failure. Am J Cardiol 50:320-4